Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there. Did your doctor somehow miss the recovery protocol that Pedro Bach-y-Rita used to recover fully back in 1958 with only a partial brain?

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Sunday, November 22, 2026

Combo of two diets may slow brain aging

 Pretty much useless; neither diet has ANY SPECIFICS!  Push hard against your doctor if this is recommended. I'd suggest laughing in their face for something this simplistic.

Combo of two diets may slow brain aging

Pairing two familiar eating plans may help your brain hang on to its youth, at least on scans. A study of more than 1,600 adults found that people who stuck more closely to the MIND diet—a mashup of the Mediterranean and DASH diets—had brain structures that looked up to 2 1/2 years "younger" over roughly 12 years of follow-up, reports CNN. Stronger adherence was tied to less loss of gray matter, which governs memory and thinking, and slower expansion of the brain's fluid-filled ventricles, another marker of atrophy.

Every three-point jump in how rigorously someone followed MIND was linked to 20% less gray-matter shrinkage and an 8% slower increase in their ventricles, researchers report in the Journal of Neurology, Neurosurgery & Psychiatry. The MIND eating plan leans hard on berries, beans, leafy greens, whole grains, nuts, fish, poultry, and olive oil, while sharply limiting red meat, butter, cheese, sweets, and fried foods.

Berries and poultry seemed to drive much of the benefits found, while sweets and fried fast food were tied to more rapid brain aging. Those latter items are "often high in unhealthy fats, trans fats, and [other end products and] may contribute to inflammation and vascular damage," the researchers say, per a release. Scientists stress that the study is observational, so it can't prove cause and effect—but they note that their findings reinforce advice to favor a Mediterranean-style nutritional regimen overall, not any single "miracle" food. (This content was created with the help of AI. Read our AI policy.)

Saturday, November 21, 2026

Stroke Rehabilitation Framework Uses Behavioural Probes to Dissect Low Engagement

 You really ARE THAT BLITHERINGLY STUPID  in not understanding that 100% recovery protocols will generate the motivation required for recovery!

You really are that blitheringly stupid that you don't understand ONE GODDAMN THING ABOUT SURVIVOR MOTIVATION/DEMORALIZATION, DO YOU? You create EXACT 100% recovery protocols, and your survivor will be motivated to do the millions of reps needed because they are looking forward to 100% recovery.  GET THERE!

Doesn't ANYONE  in stroke know how to think?

Send me personal hate mail on this: oc1dean@gmail.com. I'll print your complete statement with your name and title(If you can't stand by your name don't bother replying anonymously) and my response in my blog. Or are you afraid to engage with my stroke-addled mind? No excuses are allowed! You're medically trained; it should be simple to precisely state EXACTLY WHERE I'M WRONG. I want to hear your excuses for failure(not creating 100% recovery protocols IS FAILURE!) so I can demolish them! You aren't solving to 100% recovery protocols with NO EXCUSES!

Stroke Rehabilitation Framework Uses Behavioural Probes to Dissect Low Engagement

Precision rehabilitation aims to align therapeutic selection and delivery with the biological, functional, behavioural, and contextual characteristics of an individual, yet clinical reasoning in stroke care still frequently interprets low behavioural engagement as an undifferentiated deficit in overall motivation. In a perspective published in Frontiers in Medicine, Júlio Belo Fernandes and Valerio Sarmati argue that treating disengagement as a uniform motivational failure is increasingly difficult to sustain against emerging clinical and neuroeconomic evidence. Instead, the authors introduce motivational precision as a conceptual, decision-oriented framework designed to treat low engagement as an observable behavioural presentation that requires a mechanism-informed clinical formulation. Within this proposed clinical model, therapists would formulate competing explanations for why an individual is disengaged and apply deliberate, targeted adaptations during rehabilitation sessions to generate differential predictions regarding immediate, proximal behavioural responses.

The conceptual framework addresses a pronounced gap between existing clinical motivational strategies and the mechanistic understanding of post-stroke behaviour. While rehabilitation professionals maintain an established repertoire of interventions—including therapeutic alliance, realistic goal-setting, feedback, personalisation, emotional support, and symptom management—a 2026 systematic review identified only seventeen motor rehabilitation trials, covering 521 stroke survivors, that formally assessed both motivation and motor performance. That systematic analysis concluded that motivation remains inconsistently measured and its underlying neurological and behavioural mechanisms insufficiently understood in clinical settings. The open challenge identified by Fernandes and Sarmati is not whether motivation influences functional recovery, but why any single motivational intervention should be expected to succeed when superficially identical presentations of reduced engagement can stem from fundamentally distinct constraints.

To establish a rigorous foundation for clinical reasoning, the perspective distinguishes between motivation, behavioural engagement, and adherence, drawing on behavioural architecture such as the COM-B model, where behaviour arises through the interaction of capability, opportunity, and motivation. Motivation broadly encompasses the processes that energise and direct human action, behavioural engagement describes active physical and cognitive participation during therapy sessions, and adherence reflects the degree to which agreed therapeutic programmes are sustained over time. The authors emphasize that clinical assessments such as the Hopkins Rehabilitation Engagement Rating Scale evaluate overall engagement across rehabilitation episodes without identifying the underlying causes of disengagement. Furthermore, observed inactivity can stem from non-motivational factors, such as physical impairment, executive deficits, fatigue, or learned non-use, where the spontaneous use of a paretic limb diverges from functional capacity due to reinforcement history and past failure.


Recent empirical stroke studies cited in the perspective substantiate the premise that seemingly global deficits in drive conceal selective neurobehavioural dissociations. In a study conducted by Erfanian Abdoust and colleagues examining sixty subacute stroke patients undergoing inpatient neurorehabilitation, thirty patients clinically classified by their treating teams as having reduced drive, initiation, and endurance were compared with thirty matched patients exhibiting unaffected drive. Although both cohorts demonstrated comparable levels of self-reported depression and apathy and accepted similar proportions of effortful grip-force trials for reward, participants with clinically reduced drive failed significantly more accepted trials because they could not sustain the required isometric force for the full target duration. This finding demonstrates that an apparent lack of general drive can reflect a specific dissociation between willingness to accept effort and the capacity to sustain effort once initiated.

A complementary dissociation reported by Sporn and colleagues in forty chronic stroke survivors and thirty age-matched controls further illustrates the selective disruption of motivational components. In that study, participants executed reaching movements using a robotic exoskeleton toward visual targets with dynamic, unpredictable reward contingencies. Stroke survivors exhibited marked impairments in reward-based learning, characterized by reduced accuracy in selecting higher-value targets, fewer repetitions of rewarded actions, and computationally modelled slower updating of action-reward beliefs, particularly when using their paretic limb. In contrast, reward-based motor invigoration remained preserved: stronger reward predictions increased movement speed to the same relative extent observed in healthy control participants, even though overall movement speed was slower. These dissociations confirm that closely related motivational sub-processes can be affected independently following brain injury, making an aggregate label of low motivation an inadequate target for therapy.

To organize clinical hypotheses, the authors outline five illustrative candidate constraint domains that span different levels of analysis: low personal value or meaning of rehabilitation goals, low outcome expectancy or self-efficacy, effort-related constraints, impaired action initiation, and altered reward-based learning. Each domain organizes competing formulations across distinct psychological and neuroeconomic processes. For instance, goal value, outcome expectancy, and self-efficacy align with the Model of Therapeutic Engagement, where perceived need and anticipated success determine task entry. Effort-related constraints encompass neuroeconomic trade-offs between reward and physical effort costs, where fatigue can amplify perceived expenditure. Impaired initiation reflects an executive or apathy-related deficit in self-starting actions that may temporarily resolve with external stimulation, while altered reward-based learning reflects deficits in implicit contingency updating. The framework acknowledges that other clinical factors—such as depression, pain, cognitive impairment, or sensory neglect—can generate, amplify, or mimic these candidate constraints.

Under the motivational precision approach, clinical decision-making shifts from asking how motivated an individual is to testing what specific mechanism is constraining motivated action. The process relies on introducing a targeted therapeutic probe, defined as a deliberate rehabilitation adaptation chosen because competing formulations predict contrasting behavioural responses. The authors propose two primary forms of differential prediction: between-probe contrasts and within-response dissociations. A between-probe contrast occurs when competing hypotheses predict differing relative effects across two distinct adaptations, such as comparing a transient reduction in physical effort burden against an increase in the personal relevance of a therapeutically equivalent task. A within-response dissociation occurs when an adaptation alters a single micro-behavioural parameter while leaving others unchanged, such as an environmental initiation cue shortening initiation latency without altering subsequent task persistence.

The evaluation of these probes requires differentiating between global measures of engagement and micro-behavioural observations captured at the level of specific therapeutic tasks. Rather than relying solely on coarse session ratings, clinicians would track immediate proximal variables, including latency to initiate movement, voluntary task attempts, completed repetitions, time-on-task, persistence after error, behavioural adjustments following feedback, and autonomous choices to continue. The perspective notes that while ordinary clinical practice can rely on direct observation and brief structured documentation during standard sessions, digital devices—such as wearable movement sensors, instrumented robotic devices, and connected rehabilitation platforms—could provide objective, high-frequency measurements of initiation and persistence to refine clinical models and eventually support automated adaptive decision systems.

Implementation of this iterative procedure within routine clinical practice requires careful consideration of the expected duration and carry-over of different adaptations. In contrast, interventions expected to exert enduring effects—such as mastery-based progressions designed to enhance self-efficacy or reframing exercises around valued daily activities—are better evaluated longitudinally across consecutive sessions to observe accumulation. The authors emphasize that motivational precision must remain collaborative and person-centred: formulations should be shared transparently with the patient, therapeutic adaptations must respect individual goals, and observed proximal responses should be interpreted alongside the patient’s own subjective report.

Because the motivational precision framework is a conceptual perspective that has not yet been subjected to empirical trials, Fernandes and Sarmati emphasize that its adoption rests on rigorous scientific validation across four key requirements: discrimination, clinical value of matching, dynamic formulation, and clinical feasibility. To prove clinically useful, competing candidate formulations must reliably produce reproducibly distinct behavioural response patterns beyond non-specific benefits driven by novelty or therapist attention, which could be evaluated using counterbalanced, within-person single-case experimental designs. Most decisively, matching adaptations to verified constraints must demonstrate superior functional outcomes, adherence, or achieved therapeutic dose compared with usual stroke rehabilitation or generic motivational support. Failing either condition, the authors caution, the framework would introduce unnecessary clinical complexity without delivering genuine precision.

Subject of Research: Precision rehabilitation and decision-oriented behavioural formulation for stroke recovery

Article Title: Motivational precision: a decision-oriented approach to low rehabilitation engagement after stroke

Article References: Fernandes, J. B., & Sarmati, V. (2026). Motivational precision: a decision-oriented approach to low rehabilitation engagement after stroke. Frontiers in Medicine, 13, Article 2004950. https://doi.org/10.3389/fmed.2026.2004950

Image Credits: AI Generated

DOI: 10.3389/fmed.2026.2004950

Researchers Find Eating Less Protein May Activate Pathways Linked to Healthy Aging

 Have your competent? doctor tell you EXACTLY THE PROTEIN YOU NEED! Do not back down FROM THE EXCUSES THEY WILL USE!

Researchers Find Eating Less Protein May Activate Pathways Linked to Healthy Aging

What predicts a poor outcome in older stroke survivors? A systematic review of the literature

 What fucking stupidity: predicting failure to recover rather than DELIVERING EXACT PROTOCOLS FOR RECOVERY!

I'd fire all of you for ABSOLUTE STUPIDITY! This gets nobody recovered!

What predicts a poor outcome in older stroke survivors? A systematic review of the literature

Abstract

Purpose: To identify factors in the early post-stroke period that have a predictive value for a poor outcome, defined as institutionalization or severe disability.

Methods: MEDLINE, PSYCINFO, EMBASE and CINAHL were systematically searched for observational cohort studies in which adult and/or elderly stroke patients were assessed ≤ 1 month post-stroke and poor outcome was determined after a follow-up of ≥ 3 months.

Results: Thirty three articles were selected from 4063 records, describing 27 independent cohort studies. There are rather consistent findings that greater age, a more severe stroke (measured through a clinical evaluation scale), the presence of urinary incontinence (with impaired awareness) and a larger stroke volume (measured through brain imaging techniques) predict poor stroke outcome. In contrast to clinical expectations, the prognostic value of ADL-dependency and impaired cognition remains unclear, and factors in the domains of emotional and communicative functioning rarely feature. Studies using a selected group of stroke patients tended to identify different predictors.

Conclusions: The current evidence is insufficient for the development of a clinical prediction tool that is better than physicians' informal predictions. Future research should focus on the selection of optimal screening instruments in multiple domains of functioning, including the timing of assessment. We suggest developing prediction tools stratified by more homogeneous, clinically distinguished stroke subtypes.

Implications for rehabilitation: A reliable prognosis soon after a stroke is highly relevant to patients who ultimately have a poor outcome, because it enables early planning of care tailored to their needs(WOW! Giving up on patients from the start. Hope you feel the same when you are the 1 in 4 per WHO that has a stroke!)

  In view of the development of a clinical prediction tool that is better than physicians' informal predictions, future research should focus on optimal screening instruments in multiple domains of functioning, including emotional and communicative functioning. Clinical prediction tools stratified by more homogeneous, clinically distinguished stroke subtypes, could enable more accurate prognosis in individual stroke patients.     

Tiny robots can tumble through blood vessels to help dissolve blood clots, early test shows

ABSOLUTE FUCKING INCOMPETENCE! Let's check earlier research!

Tiny robots can tumble through blood vessels to help dissolve blood clots, early test shows

Microrobots controlled by magnets can sweep drugs towards hard-to-reach blood clots in the body, boosting the efficacy of these life-saving treatments, early tests in animals suggest.

In tests with pigs, the microbots helped to dissolve clots around 10 times faster than medication alone. The research team is now working on further safety testing to ready the technology for eventual human trials.

Negative social ties as emerging risk factors for accelerated aging, inflammation, and multimorbidity

 You've already have 5 lost years of brain cognition due to your stroke; don't let negative people steal some of your biological age! Dumping my ex solved that problem for me.

Negative social ties as emerging risk factors for accelerated aging, inflammation, and multimorbidity


Edited by James W. Moody, Duke University, Durham, NC; received June 27, 2025; accepted January 22, 2026 by Editorial Board Member Mark Granovetter
February 18, 2026
123 (8) e2515331123
 

Significance

Social relationships are fundamental to human health, yet research has focused primarily on their supportive dimensions. We investigate the role of “hasslers,” people in one’s close social networks who create problems or make life more difficult, finding that these negative ties are not rare, disproportionately experienced by individuals facing greater social and health vulnerabilities, and consequential for aging. Each additional hassler is associated with faster biological aging, with especially pronounced effects when the hassler is a family member. These findings identify negative social ties as chronic stressors that shape aging trajectories and underscore the need for interventions that reduce harmful social exposures to promote healthier aging.

Abstract

Negative social ties, or “hasslers,” are pervasive yet understudied components of social networks that may accelerate biological aging and morbidity. Using ego-centric network data and DNA methylation-based biological aging clocks (i.e., DunedinPACE and age-accelerated GrimAge2) from saliva from a state representative probability sample in Indiana, we examine how negative social ties are associated with accelerated biological aging and a broad range of health outcomes, including inflammation and multimorbidity. Negative relationships are not rare within close relationships, as nearly 30% of individuals report having at least one hassler in their network. These hasslers tend to occupy peripheral network positions and are more likely to be connected through weak, uniplex ties. Importantly, exposure to negative social ties follows patterns of social and health vulnerability, with women, daily smokers, people in poorer health, and those with adverse childhood experiences more likely to report having hasslers in their networks. Having more hasslers is associated with accelerated biological aging in both rate and cumulative burden: Each additional hassler corresponds to approximately 1.5% faster pace of aging and roughly 9 mo older biological age. Moreover, not all hasslers exert the same influence; kin and nonkin hasslers show detrimental associations, whereas spouse hasslers do not(Absolutely wrong!). Finally, a greater number of hasslers is associated with multiple adverse health outcomes beyond epigenetic aging. These findings together highlight the critical role of negative social ties in biological aging as chronic stressors and the need for interventions that reduce harmful social exposures to promote healthier aging trajectories.

Aging Redefined: Cognitive and Physical Improvement with Positive Age Beliefs

 Have your competent? doctor decipher the detailed hypothesis 2 below.

My positive outlook is over the top; having fun the rest of my life! Helped tremendously by dumping the toxic ex. I've got decades yet to enjoy life to the fullest.

Aging Redefined: Cognitive and Physical Improvement with Positive Age Beliefs


and
1
Social and Behavioral Sciences Department, Yale School of Public Health, New Haven, CT 06520, USA
2
Psychology Department, Yale University, New Haven, CT 06520, USA
3
Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06520, USA
*
Author to whom correspondence should be addressed.

Abstract

Background/Objectives: 

A widespread assumption exists among scientists, health care providers, and the public that later life is a time of inevitable and universal cognitive and physical decline. This assumption is likely due to considering older persons who improve to be exceptions, and the reliance on aging-health measures that do not allow for improvement. In contrast, we utilized a measure that allowed for an upward trajectory to occur. Our objective was to examine whether a meaningful number of older persons improve with this measure and, if so, to examine whether a promising modifiable culture-based variable, positive age beliefs, contributes to this improvement. 

Methods: 

Individuals 65 years and older, who participated in a nationally representative longitudinal study, had their physical health assessed by walking speed and their cognitive health assessed by a global performance measure. We calculated the percentage of the sample that showed improvement in each domain from baseline to the last measurement up to 12 years later. We also examined whether a positive-age-belief measure predicted this improvement in regression models. 

Results: 

It was found that 45.15% of persons improved in cognitive and/or physical function over this period, and positive age beliefs predicted these two types of improvement, both with and without adjusting for relevant covariates. 

Conclusions: 

Our findings underscore the need to instill or magnify the positivity of age beliefs and to redefine aging so that it includes the possibility of improvement.

  3.2. Hypothesis 2: Health Improvement Predicted by Positive Age Beliefs

For the primary model addressing the second hypothesis, positive age beliefs predicted improvement in cognitive health, both with (OR = 1.04, 95% CI 1.00–1.08, p= 0.049) and without covariates (OR = 1.06, 95% CI 1.02–1.10, p = 0.002), as well as in walking speed, both with (OR = 1.09, 95% 1.02–1.17, p = 0.018) and without covariates (OR = 1.11, 95% CI 1.04–1.18, p = 0.001). The same pattern was found when we repeated this model with the stasis group included (See Figure 1).
To ensure the robustness of our results with positive age beliefs as a predictor of improvement, we conducted two sets of sensitivity analyses. The first set examined whether the significant pattern of results remained when using a more conservative definition of cognitive improvement, by requiring it to be greater than 1 point. Positive age beliefs still predicted cognitive improvement, both with (OR = 1.05, 95% CI 1.00–1.11, p = 0.03) and without covariates (OR = 1.07, 95% CI 1.03–1.12, p = 0.0008). Similarly, in the model with greater than 5 cm/s walking-speed improvement as the outcome, positive age beliefs predicted it, both with (OR = 1.09, 95% CI 1.01–1.18, p = 0.023) and without covariates (OR = 1.12, 95% CI 1.04–1.20, p = 0.001).
In the second set of sensitivity analyses, conducted with the subset of participants classified as having normal cognition at baseline, positive age beliefs predicted cognitive improvement, both with (OR = 1.06, 95% CI 1.01–1.10, p = 0.02) and without covariates (OR = 1.12, 95% CI 1.08–1.16, p < 0.001). In the parallel model, conducted with those who had normal walking-speed at baseline, it was also found that positive age beliefs predicted improvement, both with (OR = 1.14, 95% CI 1.05–1.24, p = 0.0016) and without covariates (OR = 1.19, 95% CI 1.10–1.27, p < 0.001). The same pattern was found when this model was repeated with the stasis group included, both with (OR = 1.08, 95% CI 1.04–1.13, p = 0.002) and without covariates (OR = 1.14, 95% CI 1.10–1.18, p < 0.001).
In the third set of sensitivity analyses, when we combined the two earlier sensitivity analyses by using the conservative-improvement definitions with the subset of participants without deficits at baseline, the same patterns emerged. Positive age beliefs still predicted cognitive improvement, with (OR = 1.08, 95% CI 1.02–1.15, p = 0.006) and without covariates (OR = 1.16, 95% CI 1.10–1.22, p < 0.001), as well as physical-function improvement, with (OR = 1.17, 95% CI 1.07–1.29, p = 0.0009) and without covariates (OR = 1.22, 95% CI 1.20–1.32, p < 0.001).


Gut Microbiome Emerging as a Modifiable Target in Stroke Risk and Recovery

 Ask your competent? doctor what here will get you better recovery! 

No knowledge; GET THAT DOCTOR FIRED!

Gut Microbiome Emerging as a Modifiable Target in Stroke Risk and Recovery

Key Takeaways

 Unexplained residual stroke risk may be substantially mediated by microbiome-derived metabolites that influence atherogenesis, systemic inflammation, and cholesterol homeostasis beyond traditional vascular risk factor control. Modifying microbiome composition is comparatively accessible via dietary fiber manipulation, calorie restriction, prebiotics, probiotics, and fecal microbiota transplant, creating multiple prevention-oriented intervention paths.
SHOW MORE

William Roth, MD, assistant professor of neurology at the University of Chicago, discusses the role of the gut microbiome in stroke risk and recovery and emerging strategies to modify it in the acute and preventive settings.2026 Society of Vascular and Interventional Neurology (SVIN) Annual Meeting, held in Las Vegas, Nevada, marked the society’s 20th annual gathering under the chair’s theme “SVIN 2026: All In!” The meeting brought together researchers, practitioners, and industry leaders in vascular and interventional neurology, with a program of keynote lectures, interactive workshops, and poster presentations centered on advances in stroke and neurointervention. Among the sessions was a presentation titled “Microbiome and Vascular Implications,” which examined how the trillions of organisms in the gut may influence atherosclerotic disease and stroke through the metabolites they produce. Interest in the gut-brain connection has grown as clinicians look beyond traditional vascular risk factors to explain the residual risk that remains in many patients, along with potential approaches to modify the microbiome, from diet and prebiotics to probiotics and fecal transplant. William Roth, MD, assistant professor of neurology at the University of Chicago, who delivered the presentation, to discuss the topic in more depth. Roth answered questions on the central takeaways from his talk and why the microbiome is gaining traction in stroke research. He also covered how stroke itself alters the gut, which strategies could realistically be used in the acute window, and where the field should focus next. NeurologyLive: For those who may not have had a chance to attend, can you give an idea of what you talked about and why this topic is of interest to you? William Roth, MD: Part of this talk was to educate everyone that this topic has been around for as long as antiquity. Anatomists, shamans, and all sorts of thinkers dating back thousands of years have been thinking about the gut-brain connection. What we now understand is that the gut is composed of trillions of organisms that have a lot of different behaviors, especially with respect to disease, including atherosclerosis. My talk focused on helping people who don’t live in the space and work with the microbiome routinely understand some of the main takeaways from that work. That’s largely focused on the risk that certain metabolites confer to the risk of atherosclerotic disease. Focusing on the stroke field specifically, why do you think this topic has gained more traction and attention in the last couple of years? One major factor is that we still don’t prevent all strokes, even though we have identified many of the main traditional vascular risk factors and have ways to treat them. People still develop worsening carotid plaque and go on to have strokes. The traditional risk factors explain only about 20% or so of the variability of plaque size. There is a lot of residual risk that is unexplained, and I think in that world the microbiome is probably a major player. Some of the research coming out suggests that much of that residual risk, and even the risk from the traditional vascular risk factors, is heavily influenced by the microbiome.Sign in or create an account to see articles, videos, and podcasts matched to your specialties.
What’s also interesting about the gut microbiome is that there are a lot of ways you can change it. It’s a vital organ, but you don’t need transplant surgery to transplant the organ. You can change it in many different ways, and some of those are relatively easy to do. By changing your diet, the nutrients, and the fiber content, and through other strategies such as calorie restriction, you can beneficially change the composition of the microbiome. By changing the microbiome, you change a lot of upstream factors, like systemic inflammation and cholesterol homeostasis, along with other things known to exacerbate disease.Diet is not the only option. Fecal transplant is one option, as are probiotics, which are encapsulated organisms, and prebiotics, which are fiber products that can help cultivate a healthier microbiome. There are lots of different strategies we can implement to change the microbiome to help prevent stroke or serve other beneficial needs.Stroke itself seems to alter the gut microbiome, which may in turn affect recovery. How do you think about that two-way relationship between the brain and the gut?It’s very complex. We know that people who have strokes develop dysbiosis, a state of the gut microbiome characterized by lower diversity and a greater preponderance of pathogens, or organisms that we think are more proinflammatory and more injurious to health. Understanding how the microbiome changes dynamically throughout the natural history of stroke is a very interesting future research topic.In my talk, I discussed how the gut microbiome might influence stroke risk. But we also know that in the immediate aftermath of a stroke, there is a lot of inflammation and many downstream effects on the rest of the body. Seeing how the stroke affects the gut dynamically during that acute window is also interesting. We may be able to find ways to modify the microbiome in that window to help prevent some of the downstream effects that can lead to worse neurologic recovery.

What has the field been discussing in terms of potential strategies for that short acute window, and what could realistically work in a clinical care setting?

That’s a great question, because the treatment options for altering the microbiome have to fit the time frame you are trying to treat. If you are trying to prevent stroke-induced inflammation or some of the dangerous inflammatory or redox mechanisms involved in brain injury after a stroke, you can’t just give a probiotic for 6 weeks. You need something that is going to happen right now. One interesting line of inquiry is gut decontamination, in which you presume that a cohort of patients has a dysbiotic microbiome and you eliminate it with antibiotics.

There was recently a trial in traumatic brain injury where patients were given a single dose of an antibiotic, and it conferred a mortality benefit, which was very surprising. The idea was that it was preventing ventilator-associated pneumonia in patients with traumatic brain injury, but a lot of us wondered if it was also decontaminating a dangerous microbiome that would otherwise exacerbate acute brain injury. Early feeding enriched in certain prebiotics that can help cultivate a healthier microbiome might also be helpful during a short hospital stay. There are a lot of different options.

I think it’s also likely that, by understanding the microbiome and the metabolome and how they interact with disease, especially after stroke or other forms of acute brain injury, we may be led to different therapeutic routes that don’t necessarily alter the microbiome but help us identify beneficial metabolites that can prevent inflammation early on. We may not even have to touch the gut. From what we learn from the gut, we might give a short-chain fatty acid, for example, that helps in the long term. We don’t know yet, but there are certainly a lot of options and a lot of interesting work being done in the acute setting to help us better understand it.

Where does the clinical community need to spend more time and effort to further our understanding of the role of the gut microbiome in stroke?

I think first is awareness. We don’t routinely check a lab that tells us our microbiome composition, so it doesn’t occupy much of our mind share as clinicians. We don’t know exactly what to measure, and when we do, it takes a long time to get the results back, so we don’t have clinically actionable feedback. Having interviews like this, letting clinicians know that this is being actively researched, matters. It should be on your mind when you are thinking about delivering antibiotics or what kind of diet to recommend for patients. Increasing awareness will generate more interest in the stroke community.

What we need to understand the microbiome is data. We need all the clinical data that comes with performing clinical research, but we also need to measure the microbiome with samples, such as stool samples and rectal swabs, and other ways to look at circulating metabolites that are known to be modified by the microbiome.

Transcript was edited for clarity. For more SVIN 2026 coverage, click here.